Background: The standard of care for treatment of low-flow venous malformations (VMs) is percutaneous sclerotherapy. These lesions are seldom surgically resected, especially if the malformation is in an anatomically difficult location. Percutaneous sclerotherapy is safe and effective. However, the drawbacks to sclerotherapy are the need for repeated treatments and risks of skin ulceration, deep venous thrombosis, scarring/contractures, and nerve damage. Surgical resection can be difficult because of intraoperative bleeding, intraoperative lesional decompression, and difficulty in localization. Methods:
Introduction
Venous malformations (VMs) are vascular anomalies characterized by low flow and gravity dependence on clinical examination. 9 They can affect any part of the body and account for approximately one-half to two-thirds of all vascular anomalies. 5 They have an estimated prevalence of approximately 1% in the general population. 4 Elastic compression is a first-line nonoperative treatment for VMs when located in the extremities. 10 If nonoperative measures fail to control symptoms, treatment options include percutaneous sclerotherapy, surgical excision, laser photocoagulation, photodynamic therapy, or a combination thereof. 1, 2 Sclerotherapy is the preferred treatment in most vascular anomaly centers and is ideally suited for localized malformations. 2 Diffuse malformations are harder to manage and are treated with the goal of improving the most symptomatic areas rather than complete obliteration of the lesion. Common sclerosant agents include sodium tetradecyl sulfate, ethanol, and bleomycin. 1, 12 Although generally safe and effective, there are limitations to sclerotherapy. For larger VMs, repeated injections are often needed for symptomatic control. 13 Meticulous technique is required to spare normal soft tissues, including muscles, tendons, and nerves. Despite this, complications occur in up to 12% of cases and include swelling, neurologic deficits (transient or permanent), skin blistering, necrosis, hemoglobinuria, fibrosis/contractures, and renal impairment. 8 Of all the agents, ethanol is the most commonly used because of its low cost, but it is associated with the highest rate of serious complications. 2, 10 More recently, bleomycin has gained popularity for the treatment of VMs because it is thought to result in less postprocedure inflammation. There are minimal long-term data regarding efficacy of bleomycin, and there are lifetime dose limits. 12 In anatomically sensitive areas such as the deep forearm, surgical resection has the potential to offer definitive treatment while mitigating the risks of nerve and tendon damage. However, localization and complete resection can be challenging because of lesion decompression after preoperative exsanguination of the extremity and intraoperative bleeding. 7 For these reasons, surgical excision is indicated for only very localized, symptomatic lesions. 10 Staged resections can be performed for malformations that involve difficult anatomic areas of the hand and upper extremity. 13 Surgical resection of VMs can also produce poor cosmetic results and high rates of recurrence. 8 Secondary procedures are often required for release of contracture, scar revision, tissue expansion, and local flap transfer. Treatments in the forearm and hand usually require more physical therapy and rehabilitation than other locations. 13 Surgical resection and sclerotherapy are thus limited in their ability to fully obliterate VMs in complex anatomical locations such as the forearm or hand. Because of the risk of injury to nerves and tendons, these interventions must be approached with caution and are often centered on relieving focal symptoms rather than complete removal of the VM.
The purpose of this study is to report on a combined treatment approach for VMs that may provide a safer and more effective option than sclerotherapy or surgical resection alone.
Materials and Methods
This retrospective study was approved by the local institutional review board.
Patients
We reviewed medical records of patients with hand or forearm VMs who had undergone percutaneous embolization followed by surgical resection by 1 board-certified orthopedic hand surgeon. Eleven patients (6 female) underwent resections of VMs located in the hand or forearm after preoperative embolization at 27 total sites. The mean patient age was 17 years (range, 2-47 years).
Preoperative Embolization Technique
The patients in this study were percutaneously preembolized with ethylene vinyl alcohol (EVOH) copolymer (Onyx LES, ev3 Endovascular, Plymouth, Minnesota) or n-butylcyanoacrylate (n-BCA; TRUFILL n-BCA Liquid Embolic System, Codman Neuro, Raynham, Massachusetts) to facilitate en bloc surgical resection. Preoperative embolization was completed by an experienced interventional radiologist using n-BCA, EVOH copolymer 18 (6% EVOH), or EVOH copolymer 34 (8% EVOH). Lesions were analyzed for size, volume, involvement of surrounding tissues, and depth on preprocedural magnetic resonance images (MRIs) by 1 experienced musculoskeletal radiologist and 2 experienced interventional radiologists. Before the procedure, target locations were identified and circled with a skin marker to define the margins of the symptomatic areas. Patients underwent general anesthesia and intraprocedural nerve monitoring depending on the location of the lesion.
The VM was percutaneously accessed with a 21-gauge needle at multiple sites, depending on size and extent of the lesion, using ultrasound guidance. After needle placement, contrast was injected to evaluate flow dynamics and venous drainage and to estimate the amount of embolic agent required. The lesions were evaluated for the presence and size of draining veins and whether there were any areas of communication between different portions of malformation. Additional access points were obtained as needed if a portion of a VM was found to be noncommunicating with the rest of the lesion. The n-BCA or EVOH copolymer 18/34 embolic agent was prepared for injection into each site under fluoroscopic guidance. The decision to use n-BCA or EVOH copolymer was at the discretion of the interventional radiologist performing the procedure.
Careful attention was paid to the presence of draining veins to minimize distal, nontarget embolization. Embolization was stopped if increased resistance or pressure was noted or when the targeted portion of VM was fully embolized as indicated by fluoroscopy ( Figure 1a ). Access sites were then reassessed for any residual lesion using ultrasonography. The number of treatment sites and extent of embolization were determined clinically at the time of therapy. After completion of the procedure, all needles were removed, hemostasis was achieved, and the patient was transferred to the recovery room.
Surgical Technique
Surgical resection was typically performed within 1 to 7 days after the embolization (mean, 3.6 days; range, 0-14 days). Patients were placed under general anesthesia, and in all cases, the arm was elevated and exsanguination was performed from the wrist toward the upper arm, followed by inflation of a tourniquet around the upper arm. To help identify the previously embolized VM, we used a C-arm fluoroscopic unit to localize the lesion before the incision ( Figure  1b ). After initial incision, fascial layers were divided, and muscles and tendons, if not involved with the malformation, were retracted and protected. Care was taken to identify the nerves and evaluate if there was any involvement of the nerve within the VM. Lesions that had been injected with n-BCA or EVOH copolymer appeared dark and firm and were generally easily identifiable ( Figure 1c ). The lesions were then carefully excised en bloc ( Figure 1d ). If large feeding arteries were encountered, they were clamped, the tourniquet was deflated, and the distal arterial supply to the hand was evaluated to ensure adequate flow before resection. Fluoroscopy was used during and after the operation to evaluate completeness of the surgical resection ( Figure 1e ). All surgical specimens were sent for pathologic evaluation. The tourniquet was then slowly deflated to decrease systemic dissemination of any potential inflammatory components from the previous embolization procedure. The surgical wounds were closed, and a drain was left in place when possible. Postoperative conventional radiographs were also taken to monitor the extent of the surgical resection (Figures 1f and 1g ). Patients were discharged home and returned 1 week after surgery to have dressings/ drains removed and lesions evaluated. At that time, if needed, patients were referred to occupational hand therapy for fitting of custom splints and directed physiotherapy. A combined procedure performed on a VM located in the forearm is depicted in Figure 2 .
Follow-Up
Two interventional radiologists and 1 musculoskeletal radiologist independently reviewed all MRIs of the VMs, assessing for size, volume, and involvement of surrounding tissues. Assessments of embolization and surgical techniques were made by reviewing clinical notes and through direct communication with the operating interventional radiologist and surgeon. Outcomes were evaluated on the basis of operative notes and follow-up clinic visits. Follow-up included a short-interval clinic visit and then a follow-up visit within 6 to 8 weeks. Long-term follow-up is ongoing for evaluation of lesion recurrence. Follow-up imaging with ultrasonography and/or MRI was obtained as needed to evaluate for recurrence and other complications.
Results
We studied 27 malformations: 10 located in the hand, 8 in the forearm, 6 at the elbow, and 3 in the wrist. The lesions were evaluated for size and involvement of surrounding soft tissues on the preprocedural MRI. Because of motion artifact or suboptimal MRI acquisition, 6 lesions could not be assessed for size, and 3 lesions could not be assessed for soft-tissue involvement. The mean lesion volume was 9.4 mL (range, 0.95-43.5 mL). There was nerve involvement in 75% of the lesions (18 of 24), and tendon involvement in 25% (6 of 24). Twenty-five percent (6 of 24) of the lesions were subcutaneous, 29% (7 of 24) were subcutaneous and intramuscular, 29% (7 of 24) were intramuscular, and 17% (4 of 24) were intramuscular and periosseous. EVOH copolymer was used to treat 19 of the 27 malformations (mean volume, 3.9 mL; range, 0.5-14.9 mL), and n-BCA was used to treat the remaining 8 lesions (mean volume, 2.4 mL; range, 0.6-5.5 mL). Long-term follow-up of these cases is ongoing. Detailed follow-up information for the 11 patients is provided in Table 1 . The VMs were classified as focal if there was 1 discrete VM within the extremity, multifocal if there were 2 or more discrete VMs located in different parts of the extremity, or diffuse if there was VM involvement throughout the extremity. In total, there were 5 focal VMs, 3 multifocal VMs, and 3 diffuse VMs. Of the 5 patients with focal VMs, 4 showed near-complete resolution of the treated lesions on follow-up; 1 patient was lost to follow-up. Three patients with focal VMs have more than 3 years of followup, and one has 1 year of follow-up. Of the 3 patients with multifocal VMs, 2 were lost to follow-up. The other has 2 years of follow-up with recurrence of the lesions at all 3 treatment sites; however, no repeat treatments have been performed. All 3 patients with diffuse VMs have required continued treatment. In these patients, 14 lesions were treated, and all but 1 of these sites have required repeat intervention. The 1 site that did not require repeat intervention was a focal lesion near the elbow, isolated from the other areas of diffuse VM. No major functional impairments were reported in any patient. There were no major procedure-related complications from the embolization procedure or the surgical resection in any patient. Blood loss was minimal in all cases, and no patient required a blood transfusion. All patients were monitored overnight in the hospital after both procedures and were discharged home the next day.
Discussion
This study represents our initial clinical experience using the combined approach of percutaneous embolization and subsequent surgical resection to treat VMs of the forearm and hand. The advantage of preembolizing a VM before resection is the transformation of an otherwise friable lesion with indistinct boundaries into one that readily collapses into a firm mass more easily dissected and surgically removed en bloc. When resection of a VM is done without embolization, there is collapse and spillage of blood, often making it difficult to delineate the boundaries of the lesion. Leakage further makes it difficult to determine whether the VM has been completely resected. The preembolization of VMs with EVOH copolymer or n-BCA before removal or debulking thus greatly facilitated surgical resection.
Definitive treatment measures for VMs have been elusive. Currently, the "gold standard" is percutaneous sclerotherapy. However, patients, especially those with diffuse or large VMs, often need repeated sclerotherapy, which increases the risk of a complication. In addition, percutaneous sclerotherapy is limited near complex structures close to tendons and nerves of the forearm. Percutaneous sclerotherapy is thus often targeted to only the most accessible, symptomatic areas of the VM. By using the combined approach of preembolization with n-BCA or EVOH copolymer followed by surgical resection, we hoped to provide patients with a more definitive treatment option.
In the cases presented here, embolization provided a clearly demarcated target for lesion resection. Intraoperatively, it was found that in all cases, preresection embolization allowed for clear visualization of the target lesions and facilitated resection because key structures such as nerves and tendons were easily identified. This technique has been useful in other regions of the body with lesions in close proximity to complex structures such as in the head and neck. In 2008, Cil et al 3 described the treatment of VMs in the craniofacial region in 13 patients. In 2011, Garcia et al 6 described the treatment of low-flow venous lesions of the orbit in 3 patients. In addition, our results are in line with the currently published research. The largest published series to date are the reports by Upton et al 13 and Sofocleous et al. 11 Upton et al 13 reported on 125 VMs of the upper extremity, most of which were treated surgically. Unfortunately, no outcome data were reported, but they did report a complication rate of 22%. Sofocleous et al 11 reported treating 17 patients with VMs of the upper extremity. Of these 17 patients, embolization was attempted in 13 patients, with 12 reporting initial symptomatic improvement. The mean symptom-free interval was 30.5 months.
The combined technique reported here had more durable results in patients with focal VMs than in those with multifocal VMs or diffuse VM involvement of the entire extremity. Our initial experience did not include enough patients to make definitive conclusions in this regard, but 4 of 5 patients with focal VMs showed at least near-complete resolution of the treated lesion. The other patient was lost to follow-up, so it is unclear if the treated VM resolved. In all 3 patients with diffuse VMs, symptoms failed to improve and treatment remains ongoing. Interestingly, in one of the patients with a diffuse VM, an isolated VM was treated near the elbow, and this lesion has not recurred and the focal area of pain at the elbow has resolved. This fits with our overall impression that, at this time, this combined treatment technique is best reserved for more focal lesions.
This study is limited by the fact that it is retrospective, that it lacks a "control" arm of sclerotherapy or surgery alone, and that it has a small sample size with limited follow-up. Although we are optimistic that our combined approach will provide patients with another safe and effective treatment option, this technique has limitations. Access to physicians who are willing to perform these complex procedures is limited, and coordination of multiple procedures can be challenging if the proper infrastructure is not in place. Another drawback of preembolization is the high cost of agents like EVOH copolymer and TRUFILL n-BCA. Our results show that using our combined technique had poor results in patients with multifocal or diffuse VM involvement of the extremity. Further investigation of this combined technique is warranted to better identify the ideal patient and to compare long-term outcomes with those of sclerotherapy or surgical resection alone.
Conclusion
A combined approach of preoperative embolization followed by surgical resection appears to be a safe and effective treatment for focal VMs of the hand and forearm but may not be adequate for patients with multifocal VMs or diffuse VM involvement of the extremity. Further study is warranted to determine if this combined approach offers a more effective and durable alternative to the use of sclerotherapy or surgical resection alone.
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